{"id":"NCT00322153","sponsor":"Forest Laboratories","briefTitle":"A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2007-10","completion":"2008-01","firstPosted":"2006-05-05","resultsPosted":"2010-09-16","lastUpdate":"2010-09-16"},"enrollment":677,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dementia of the Alzheimer's Type"],"interventions":[{"type":"DRUG","name":"memantine ER","otherNames":["Namenda XR"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Memantine ER","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).","primaryOutcome":{"measure":"Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.4,"sd":0.65},{"arm":"Memantine ER","deltaMin":2.2,"sd":0.65}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":83,"countries":["United States","Argentina","Chile","Mexico"]},"refs":{"pmids":["29771687"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":335},"commonTop":["Fall","Urinary tract infection","Headache","Diarrhoea"]}}